Antidepressant-like effects of kynurenic acid in a modified forced swim test

Tanaka, Masaru; Bohár, Zsuzsanna; Martos, Diána; Telegdy, Gyula; Vécsei, László

doi:10.1007/s43440-020-00067-5

Cited by 68 publications

(65 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another recent study also suggested that KYNA would be a potential biomarker in diagnosing depression patients 28 . In addition to reduced KYNA levels in MDD, a recent study demonstrated that the administration of KYNA induced antidepressant-like effects in an animal model of depression 29 .…”

Section: Discussionmentioning

confidence: 99%

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Erabi

Okada

Shibasaki

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Since optimal treatment at an early stage leads to remission of symptoms and recovery of function, putative biomarkers leading to early diagnosis and prediction of therapeutic responses are desired. The current study aimed to use a metabolomic approach to extract metabolites involved in both the diagnosis of major depressive disorder (MDD) and the prediction of therapeutic response for escitalopram. We compared plasma metabolites of MDD patients (n = 88) with those in healthy participants (n = 88) and found significant differences in the concentrations of 20 metabolites. We measured the Hamilton Rating Scale for Depression (HRSD) on 62 patients who completed approximately six-week treatment with escitalopram before and after treatment and found that kynurenic acid and kynurenine were significantly and negatively associated with HRSD reduction. Only one metabolite, kynurenic acid, was detected among 73 metabolites for overlapped biomarkers. Kynurenic acid was lower in MDD, and lower levels showed a better therapeutic response to escitalopram. Kynurenic acid is a metabolite in the kynurenine pathway that has been widely accepted as being a major mechanism in MDD. Overlapping biomarkers that facilitate diagnosis and prediction of the treatment response may help to improve disease classification and reduce the exposure of patients to less effective treatments in MDD.

show abstract

Section: Discussionmentioning

confidence: 99%

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Erabi

Okada

Shibasaki

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Additionally, 15 days of supplementation of FO as a source of omega-3 fatty acid to PPD-like rats have successfully reduced their immobility time in FST [ 13 , 17 ]. However, there is paucity of information with regards to the effects of FO on active behaviors, swimming and climbing time in PPD-like rats, as increased swimming time and decreased immobility time in FST is an indicator that the rats being tested are less depressed [ 33 ]. The present study showed that FO significantly increased the swimming time, but decreased the climbing time of the PPD-like rats.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant-Like Properties of Fish Oil on Postpartum Depression-Like Rats Model: Involvement of Serotonergic System

et al. 2020

View full text Add to dashboard Cite

Pathophysiology of postpartum depression (PPD) has been associated with many factors, such as neuroendocrine, neuroinflammation and neurotransmitter changes. Fish oil (FO) improves PPD both in humans and animals. However, little is known with regards to its pharmacology on a PPD-like rat model. Hence, the current study aimed at investigating the effects of FO on a PPD-like rat model. Female rats were induced with PPD-like symptoms and then randomly divided into six groups (n = 6) for two experimental protocols. Protocol 1 consisted of PPD-like rats (2 mL distilled water), PPD-like + FO (9 g/kg/d) and PPD-like + Fluoxetine (FLX) (15 mg/kg/d) groups of rats, whereas Protocol 2 consisted of PPD-like rats (2 mL distilled water) + PCPA (p-chlorophenylalanine) 150 mg/kg, PPD-like + FO (9 g/kg/d) + PCPA 150 mg/kg and PPD-like + FLX (15 mg/d) + PCPA 150 mg/kg groups of rats, respectively. All treatments were administered orally for 10 days postpartum, except PCPA, which was given intraperitoneally. Prior to euthanasia, the antidepressant-like effect of the FO was evaluated using the forced swimming test (FST) and open field test (OFT) on day 10 postpartum. Biochemical analysis of serotonin, serotonin metabolite and serotonin turnover from their prefrontal cortex and hippocampus were also measured. The results showed that FO decreased immobility time and increased swimming time significantly, but not climbing time in FST. Further, it also decreased serotonin metabolite and turnover significantly in the hippocampus of the PPD-like rats. In contrast, administration with PCPA reversed all the outcomes. The antidepressant-like effects of FO were found to be similar with that of FLX. Thus, it can be concluded that FO exerts its antidepressant-like effects in PPD-like rats through modulation of serotonergic system.

show abstract

“…The rs9657182 SNP is linked to moderate or severe IFN-α-induced depressive symptoms in Caucasian patients with chronic hepatitis C. The SNP is located in the linkage disequilibrium block encompassing 20 kilobases upstream of IDO1 as well as includes at least six additional polymorphisms that may contain binding sites for immunoregulatory proteins or may have epigenetic regulatory function [30]. In addition, a downstream metabolite kynurenic acid was found an antidepressant in animal mode of depression [44]. Indoximod is a methylated TRP that inhibits IDO to maintain or elevate TRP levels important to T cell function.…”

Section: Discussionmentioning

confidence: 99%

Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase Influenced the Age Onset of Parkinson’s Disease

Török¹,

Maszlag-Török²,

Molnár³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Earlier studies reported alterations of the kynurenine (KYN) pathway of tryptophan (TRP) metabolism in Parkinson’s disease (PD). The first rate-limiting enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan dioxygenase were observed upregulated, resulting elevated KYN/TRP ratios in the serum and cerebrospinal fluid samples of patients with PD. An increasing number of single nucleotide polymorphisms (SNPs) has been identified in a population of PD. However, little is known if genetic variations of the IDO contribute to disturbance of the KYN metabolism in and the pathogenesis of PD. SNP analysis of IDO1 was performed by allelic discrimination assay with fluorescently labelled TaqMan probes and a subgroup analysis was conducted according to the age of PD onset. The frame shifts variant rs34155785, intronic variant rs7820268, and promotor region variant rs9657182 SNPs of 105 PD patients without comorbidity were analyzed and compared to 129 healthy controls. No significant correlation was found in three SNPs between PD patients and healthy controls. However, the subgroup analysis revealed that A alleles of rs7820268 SNP or rs9657182 SNP carriers contribute to later onset of PD than non-carriers. The study suggested that SNPs of IDO1 influenced the age onset of PD and genotyping of SNPs in certain alleles potentially serves as a risk biomarker of PD.

show abstract

Antidepressant-like effects of kynurenic acid in a modified forced swim test

Cited by 68 publications

References 17 publications

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Antidepressant-Like Properties of Fish Oil on Postpartum Depression-Like Rats Model: Involvement of Serotonergic System

Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase Influenced the Age Onset of Parkinson’s Disease

Contact Info

Product

Resources

About